CoChat

Prioritizing Future Research on Off‐Label Prescribing: Results of a Quantitative Evaluation

Open access
Walton, Surrey M., Schumock, Glen T., Lee, Ky‐Van, Alexander, G. Caleb, Meltzer, David, Stafford, Randall S. · 2008 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Cited by 96

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Study Objective. To develop a prioritized list of individual drugs for which future research regarding off‐label uses is warranted. Design. Retrospective, cross‐sectional study. Data Sources. Commercial database that provides ongoing estimates of drug prescribing practices of office‐based physicians in the United States and an Internet database of comprehensive evidence‐based drug information. Measurements and Main Results. The base analyses incorporated three key factors based on the theory of value of information: volume of off‐label use with inadequate evidence, drug safety, and cost and market considerations. Nationally representative prescribing data were used to estimate the number of off‐label drug uses by indication from January 1, 2005‐June 30, 2007, in the United States, and these indications were then categorized according to the adequacy of scientific support. Black‐box warnings and safety alerts, drug cost, date of market entry, and marketing expenditures were also incorporated into the final model to produce a priority score. Sensitivity analyses were conducted by varying key model parameters. Our findings identified a high volume of off‐label prescribing in the absence of good evidence for a substantial number of drugs, particularly antidepressants, antipsychotics, and anxiolytic‐sedatives. Drugs that consistently ranked high in both our base model and sensitivity analyses were quetiapine, warfarin, escitalopram, risperidone, montelukast, bupropion, sertraline, venlafaxine, celecoxib, lisinopril, duloxetine, trazodone, olanzapine, and epoetin alfa. Conclusion. Future research into off‐label drug use should focus on drugs used frequently with inadequate supporting evidence, particularly if further concerns are raised by known safety issues, high drug cost, recent market entry, and extensive marketing. Our quantitative analysis identified particular concerns with the off‐label use of antipsychotic and antidepressant drugs. Targeted research and policy activities on our list of prioritized drugs have high potential value.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1592/phco.28.12.1443

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Walton, S. M., Schumock, G. T., Lee, K., Alexander, G. C., Meltzer, D., & Stafford, R. S.
Venue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher
Wiley
Published
2008-12
Volume
28
Issue
12
Pages
1443-1452
ISSN
  • 0277-0008 (ISSN-L)
  • 1875-9114
OpenAlex
W2171049004
Cited by
96
References
3
FWCI
23.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.